The TrialNet natural history study of the development of type 1 diabetes: Objectives, design, and initial results

Pediatric Diabetes

Volumn 10, Issue 2, 2009, Pages 97-104

  Mahon, Jeffrey L ^a,i   Sosenko, Jay M ^b   Rafkin Mervis, Lisa ^b   Krause Steinrauf, Heidi ^c   Lachin, John M ^c   Thompson, Clinton ^c   Bingley, Polly J ^d   Bonifacio, Ezio ^e   Palmer, Jerry P ^f   Eisenbarth, George S ^g   Wolfsdorf, Joseph ^h   Skyler, Jay S ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF MIAMI   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h BOSTON CHILDREN S HOSPITAL   (United States)

ⁱ NONE   (Canada)

Author keywords

Natural history; Pre type 1 diabetes

Indexed keywords

AUTOANTIBODY; GLUTAMATE DECARBOXYLASE; INSULIN; PANCREAS ISLET CELL ANTIBODY; RNA;

ADOLESCENT; ADULT; ANAMNESIS; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE DURATION; DISEASE MARKER; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOASSAY; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; T LYMPHOCYTE;

ADOLESCENT; ADULT; ALGORITHMS; AUTOANTIBODIES; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INFANT; MALE; MASS SCREENING; MIDDLE AGED; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RESEARCH DESIGN; RISK FACTORS; YOUNG ADULT;

EID: 61549136296     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2008.00464.x     Document Type: Article

References (35)

1. Atkinson MA, Eisenbarth GS. Type 1 diabetes: New perspectives on disease pathogenesis and treatment. Lancet 2001: 353: 221-229.
2. Greeenbaum CJ, Harrison LC. Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes 2003: 52: 1059-1065.
3. The Diabetes Prevention Trial-T ype 1 Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002: 346: 1685-1691.
4. European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. ENDIT: a randomized controlled trial of intervention before onset of type 1diabetes. Lancet 2004: 363: 925-931.
5. The Diabetes Prevention Trial-Type 1 Study Group. Effects of oral insulin in relatives of patients with type 1 diabetes. Diabetes Care 2005: 28: 1068-1076.
6. The Canadian-European Randomized Control Trial Group. Cyclosporine-induced remission of IDDM after early intervention. Diabetes 1988: 37: 1574-1587.
7. Herold KC, Hagopian W, Auger JA et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002: 346: 1692-1698.
8. Skyler JS. Prediction, and prevention of type 1 diabetes: Progress, problems, and prospects. Clin Pharmacol Ther 2007: 81: 768-771.
9. Krischer JP, Cuthbertson DD, Yu L et al. Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes. J Clin Endocrinol Metab 2003: 88: 103-108.
10. Rotrosen D, Matthews JB, Bluestone JA. The immune tolerance network: A new paradigm for developing tolerance-inducing therapies. J Allergy Clin Immunol 2002: 110: 17-23.
11. Type 1 Diabetes-Trial Net Study Group. Natural History Study of the development of type 1 diabetes (Protocol TN-01). (available from http://www.diabetestrialnet.org/doc/nhs_pro.pdf). Accessed 17 April 2007.
12. Last JM ed. A Dictionary of Epidemiology. New York: Oxford University Press, 2001: 121.
13. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical Epidemiology: A Basic Science for Clinical Medicine. Boston, MA: Little, Brown, and Company, 1991.
14. Fletcher RH, Fletcher SW, Wagner EH. Clinical Epidemiology: The Essentials. Baltimore, MD: Williams and Wilkins, 1988.
15. Rothman KJ, Greenland S. Modern Epidemiology. Philadelphia, PA: Lippincott, Williams, and Wilkins, 1998.
16. Schatz D, Krischer J, Horne G et al. Islet cell antibodies predict insulin-dependent diabetes in United States school age children as powerfully as unaffected relative. J Clin Invest 1994: 93: 2403-2407.
17. Wang J, Miao D, Babu S et al. Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity. J Clin Endocrinol Metab 2007: 92: 88-92.
18. Sosenko JM, Krischer JP, Palmer JP et al.,
19. for the Diabetes Prevention Trial-Type 1 (DPT-1) Study Group. A risk score for type 1 diabetes derived from autoantibody-positive participants in the DPT-1. Diabetes Care 2008: 31: 528-533.
20. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997: 20: 1183-1197.
21. Lachin JM. Biostatistical Methods: The Assessment of Relative Risks. New York: John Wiley and Sons, 2000.
22. Gorsuch AN, Spencer KM, Lister J et al. Evidence for a long prediabetic period in type I (insulin-dependent) diabetes mellitus. Lancet 1981: 2: 1363-1365.
23. Roep BO. The role of T-cells in the pathogenesis of type 1 diabetes: from cause to cure. Diabetologia 2003: 46: 305-321.
24. Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC. Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetelogia 2004: 47: 1661-1667.
25. Mrena S, Virtanen SM, Laippala P, Hannila ML, Akerblom HK, Knip M. Models for predicting type 1 diabetes in siblings of affected children. Diabetes Care 2006: 29: 662-667.
26. Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP, for the Diabetes Prevention Trial-Type 1 Study Group. Role of insulin resistance in predicting progression to type 1 diabetes. Diabetes Care 2007: 30: 2314-2320.
27. Bingley PJ, Mahon JL, Gale E, for the ENDIT Study Group. Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetes Care 2008: 31: 146-150.
28. Barker JM, Goehrig SH, Barriga K et al.
29. for the DAISY study. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care 2004: 27: 1399-1404.
30. Bingley PJ, Gale EA; European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: The role of additional immune, genetic and metabolic markers of risk. Diabetologia 2006: 49: 881-890.
31. Vist GE, Hagen KB, Devereaux PJ, Bryant D, Kristoffersen DT, Oxman AD. Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database Syst Rev 2007: 2: MR000009.
32. Sosenko JM, Palmer JP, Greenbaum CJ et al. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006: 29: 643-649.
33. Hagopian WA, Lernmark A, Rewers MJ et al. TEDDY -The Environmental Determinants of Diabetes in the Young: An observational clinical trial. Ann N Y Acad Sci 2006: 1079: 320-326.
34. The TRIGR Study Group. Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR). Pediatr Diabetes 2007: 8: 117-137.
35. Kimpimäki T, Kupila A, Hämäläinen AM et al. The first signs of beta-cell autoimmunity appear in infancy in genetically susceptible children from the general population: The Finnish Type 1 Diabetes Prediction and Prevention Study. J Clin Endocrinol Metab 2001: 86: 4782-4788.